Processa Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $4.76M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2022 Ended Dec 31, 2022 | Mar 31, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 8, 2022 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 12, 2022 | During market hours | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 13, 2021 | Before market open | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | May 13, 2021 | After market close | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Mar 25, 2021 | After market close | – | – | – |
Press releases
Announcements Processa Pharmaceuticals filed with the SEC
You should carefully consider the risks described below, as well as general economic and business risks and the other
Other events · EX-99.4 to Form 8-K/A
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Other events · EX-99.5 to Form 8-K/A
PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO
Material agreement · Agreement terminated · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Agreement terminated · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Provides Portfolio and Business Update
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Pricing of $7 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The- Market Under Nasdaq Rules
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Provides Product Pipeline and Financial Update
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Names Russell L. Skibsted as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K